We conclude that this vaccine combination is associated with antigen-specific immunological responses and can generate activated hTERT-specific CD4+/CD8+ effector responses against this tumour associated antigen in patients with therapy-resistant solid tumours. The gene discussed is CD4; the disease is neoplasm.